PROM1 and neoplasm: In the present manuscript, we built a CD133+ specific peptide TR modified NLC (T-NLC), it's in vitro active tumor targeting effect was validated using Cou6 as the fluorescent probe, it's in vitro tumor inhibition effect was confirmed using Sal as the model drug.